Drugs / HRS-5632
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06732154 | Dec 2024 → Mar 2026 | hyperlipidemia | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07185776 | Oct 2025 → Apr 2027 expected | hypolipoproteinemia | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-5632 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07185776 ↗ |
| Route | Subcutaneous | “Single Subcutaneous Injection” NCT06732154 ↗ |